ProKidney (NASDAQ:PROK – Get Free Report) and BeOne Medicines (NASDAQ:ONC – Get Free Report) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, institutional ownership, profitability, analyst recommendations, risk, dividends and valuation.
Insider and Institutional Ownership
51.6% of ProKidney shares are held by institutional investors. Comparatively, 48.6% of BeOne Medicines shares are held by institutional investors. 39.8% of ProKidney shares are held by insiders. Comparatively, 6.2% of BeOne Medicines shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
Analyst Recommendations
This is a summary of current ratings for ProKidney and BeOne Medicines, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| ProKidney | 2 | 1 | 4 | 1 | 2.50 |
| BeOne Medicines | 1 | 2 | 11 | 1 | 2.80 |
Profitability
This table compares ProKidney and BeOne Medicines’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| ProKidney | -8,131.50% | N/A | -21.39% |
| BeOne Medicines | 8.94% | 12.06% | 6.69% |
Earnings and Valuation
This table compares ProKidney and BeOne Medicines”s top-line revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| ProKidney | $889,000.00 | 614.99 | -$68.99 million | ($0.53) | -3.42 |
| BeOne Medicines | $5.34 billion | 6.16 | $286.93 million | $4.47 | 67.12 |
BeOne Medicines has higher revenue and earnings than ProKidney. ProKidney is trading at a lower price-to-earnings ratio than BeOne Medicines, indicating that it is currently the more affordable of the two stocks.
Volatility & Risk
ProKidney has a beta of 1.7, indicating that its stock price is 70% more volatile than the S&P 500. Comparatively, BeOne Medicines has a beta of 0.5, indicating that its stock price is 50% less volatile than the S&P 500.
Summary
BeOne Medicines beats ProKidney on 9 of the 14 factors compared between the two stocks.
About ProKidney
ProKidney Corp., a clinical-stage biotechnology company, provides transformative proprietary cell therapy platform for treating various chronic kidney diseases in the United States. The company's lead product is Renal Autologous Cell Therapy (REACT), an autologous homologous cell admixture, which has completed Phase I clinical trial for REACT in patients with congenital anomalies of the Kidney and Urinary Tract (CAKUT), as well as in Phase III and Phase II clinical trials for the treatment of moderate to severe diabetic kidney disease. ProKidney Corp. founded in 2015 and is headquartered in Winston-Salem, North Carolina.
About BeOne Medicines
BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in Basel, Switzerland.
Receive News & Ratings for ProKidney Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ProKidney and related companies with MarketBeat.com's FREE daily email newsletter.
